# Liste der umsatzstärksten Arzneimittel

Diese Liste enthält die umsatzstärksten Arzneimittel.

## Weltweit
### 2022

| Rang | Präparatename | Wirkstoff(e) | Umsatz in Mrd. USD | Zulassungsinhaber | Wirkstoffgruppe |
| 1 | Comirnaty | BNT162b2 | 37,81 | Pfizer | mRNA-Impfstoffe |
| 2 | Humira | Adalimumab | 21,24 | AbbVie | TNF-Blocker |
| 3 | Keytruda | Pembrolizumab | 20,94 | MSD Sharp & Dohme | Checkpoint-Inhibitoren |
| 4 | Paxlovid | Ritonavir/Nirmatrelvir | 18,93 | Pfizer | Virostatika |
| 5 | Spikevax | mRNA-1273 | 18,44 | Moderna | mRNA-Impfstoffe |
| 6 | Eliquis | Apixaban | 11,79 | Bristol-Myers Squibb | Antikoagulantien |
| 7 | Biktarvy | Bictegravir/Emtricitabine/Tenofovir alafenamide | 10,39 | Gilead Sciences | Virostatika |
| 8 | Revlimid | Lenalidomide | 9,98 | Bristol-Myers Squibb | Immunmodulatoren |
| 9 | Stelara | Ustekinumab | 9,72 | Janssen-Cilag | Immunmodulatoren |
| 10 | Eylea | Aflibercept | 9,64 | Regeneron Pharmaceuticals | Antineoplastika |
| 11 | Opdivo | Nivolumab | 9,30 | Bristol Myers Squibb | Checkpoint-Inhibitoren |
| 12 | Dupixent | Dupilumab | 9,10 | Regeneron, Sanofi | Immunmodulatoren |
| 13 | Ozempic | Semaglutide | 8,71 | Novo Nordisk | Inkretinmimetika |
| 14 | Jardiance | Empagliflozin | 8,39 | Boehringer Ingelheim, Eli Lilly & Co | SGLT2-Inhibitoren |
| 15 | Imbruvica | Ibrutinib | 8,35 | Pharmacyclics LLC, AbbVie, Janssen Biotech | Tyrosinkinase-Inhibitoren |
| 16 | Darzalex | Daratumumab | 7,98 | Janssen Biotech | |
| 17 | Trikafta | Elexacaftor/Tezacaftor/Ivacaftor | 7,69 | Vertex Pharmaceuticals | |
| 18 | Trulicity | Dulaglutide | 7,44 | Eli Lilly & Co | Inkretinmimetika |
| 19 | Xarelto | Rivaroxaban | 7,22 | Janssen-Cilag | Antikoagulantien |
| 20 | Gardasil | 9-valenter Humaner Papillomvirus-Impfstoff | 6,90 | Merck & Co. | Impfstoffe |
| Quelle: ||||||

### 2018

| Rang | Präparatename | Wirkstoff(e) | Umsatz in Mrd. USD | Umsatz in Mrd. USD | Zulassungsinhaber | Wirkstoffgruppe |
| 1 | Humira | Adalimumab | 19,9 | 20,47 | AbbVie | TNF-Blocker |
| 2 | Revlimid | Lenalidomid | 9,7 | 9,69 | Celgene | Immunmodulatoren |
| 3 | Keytruda | Pembrolizumab | 7,2 | 7,17 | MSD Sharp & Dohme | Immunmodulatoren |
| 4 | Herceptin | Trastuzumab | 7,1 | 7,05 | Roche | Krebsimmuntherapeutika |
| 5 | Avastin | Bevacizumab | 7 | 6,92 | Roche | Antineoplastika |
| 6 | Rituxan/MabThera | Rituximab | 6,9 | 6,82 | Roche | Antineoplastika |
| 7 | Opdivo | Nivolumab | 6,7 | 7,57 | Bristol-Myers Squibb | Checkpoint-Inhibitor |
| 8 | Eliquis | Apixaban | 6,4 | 9,87 | Bristol-Myers Squibb | Antikoagulanzien |
| 9 | Prevenar 13 | Pneumokokkenpolysaccharide | 5,72 | 5,80 | Pfizer | Pneumokokkenimpfstoff |
| 10 | Stelara | Ustekinumab | 5,7 | 5,25 | Johnson & Johnson | Interleukininhibitor |
| | Enbrel | Etanercept | | 7,45 | Amgen, Pfizer, Takeda | Antirheumatika |
| | Xarelto | Rivaroxaban | | 6,85 | Bayer, Johnson & Johnson | Antikoagulantien |
| | Imbruvica | Ibrutinib | | 6,61 | AbbVie, Johnson & Johnson | Tyrosinkinase-Inhibitoren |
| | Eylea | Aflibercept | | 6,55 | Bayer, Regeneron | Antineoplastika |
| | Remicade | Infliximab | | 6,44 | Johnson & Johnson, MSD, Mitsubishi Tanabe | TNF-Blocker |

### 2017

| Rang | Präparatename | Wirkstoff(e) | Umsatz in Mrd. USD | Zulassungsinhaber | Wirkstoffgruppe |
| 1 | Humira | Adalimumab | 18,946 | AbbVie | TNF-Blocker |
| 2 | Enbrel | Etanercept | 8,262 | Amgen, Pfizer, Takeda | Antirheumatika |
| 3 | Eylea | Aflibercept | 8,26 | Bayer, Regeneron | Antineoplastika |
| 4 | Revlimid | Lenalidomid | 8,187 | Celgene | Immunmodulatoren |
| 5 | Rituxan/MabThera | Rituximab | 7,831 | Roche | Antineoplastika |
| 6 | Remicade | Infliximab | 7,83 | Johnson & Johnson, Merck, Mitsubishi Tanabe | TNF-Blocker |
| 7 | Herpectin | Trastuzumab | 7,435 | Roche | Krebsimmuntherapeutika |
| 8 | Eliquis | Apixaban | 7,395 | Bristol-Myers Squibb | Antikoagulanzien |
| 9 | Avastin | Bevacizumab | 7,089 | Roche | Antineoplastika |
| 10 | Xarelto | Rivaroxaban | 6,590 | Bayer, Johnson & Johnson | Antikoagulantien |
| 11 | Opdivo | Nivolumab | 5,815 | Bristol-Myers Squibb, Ono Pharmaceutical | Checkpoint-Inhibitor |
| 12 | Lantus | Insulin glargin | 5,731 | Sanofi | Antidiabetika |
| 13 | Prevenar 13 | Pneumokokkenpolysaccharide | 5,601 | Pfizer | Pneumokokkenimpfstoff |
| 14 | Lyrica | Pregabalin | 5,318 | Pfizer, Eisai | Antikonvulsiva |
| 15 | Neulasta | Pegfilgrastim | 4,553 | Amgen, Kyowa Hakko Kirin | Immunstimulantien |

### 2015

| Rang | Präparatename | Wirkstoff(e) | Umsatz in Mrd. USD | Zulassungsinhaber | Wirkstoffgruppe |
| 1 | Humira | Adalimumab | 16,07 | AbbVie | TNF-Blocker |
| 2 | Harvoni | Ledipasvir und Sofosbuvir | 9,08 | Gilead Sciences | Virustatika |
| 3 | Enbrel | Etanercept | 8,87 | Amgen | Antirheumatika |
| 4 | Rituxan | Rituximab | 8,53 | Roche | Antineoplastika |
| 5 | Remicade | Infliximab | 7,83 | Johnson & Johnson | TNF-Blocker |
| 6 | Revlimid | Lenalidomid | 6,97 | Celgene | Immunmodulatoren |
| 7 | Avastin | Bevacizumab | 6,752 | Roche | Antineoplastika |
| 8 | Herpectin | Trastuzumab | 6,75 | Roche | Krebsimmuntherapeutika |
| 9 | Lantus | Insulin glargin | 6,05 | Sanofi | Antidiabetika |
| 10 | Prevenar 13 | Pneumokokkenpolysaccharide | 5,72 | Pfizer | Pneumokokkenimpfstoff |

### 2013

Nach Zusammenstellung an der Uni Freiburg.
| Rang | Wirkstoff | Umsatz in Mrd. USD | Hersteller | Wirkstoffgruppe |
| 1 | Adalimumab | 10,058 | AbbVie | TNF-Blocker |
| 2 | Fluticason + Salmeterol | 9,064 | GlaxoSmithKline | Corticosteroide + Beta-2-Sympathomimetika |
| 3 | Etanercept | 8,096 | Amgen | TNF-Blocker |
| 4 | Rosuvastatin | 8,025 | AstraZeneca | Statine |
| 5 | Infliximab | 7,805 | Johnson & Johnson, MSD | TNF-Blocker |
| 6 | Esomeprazol | 7,773 | AstraZeneca | Protonenpumpenhemmer |
| 7 | Insulin glargin | 7,773 | Sanofi-Aventis | Insulinanaloga |
| 8 | Aripiprazol | 7,697 | Bristol-Myers Squibb, Otsuka | Atypische Neuroleptika |
| 9 | Duloxetin | 6,373 | Eli Lilly and Company | Serotonin-Noradrenalin-Wiederaufnahmehemmer |
| 10 | Rituximab | 6,154 | Roche | Monoklonale Antikörper: CD20 |
| 11 | Bevacizumab | 5,518 | Roche | Angiogenese-Inhibitoren |
| 12 | Tiotropiumbromid | 5,256 | Boehringer Ingelheim | Anticholinergika |
| 13 | Trastuzumab | 5,064 | Roche | Monoklonale Antikörper: HER2/neu |
| 14 | Pregabalin | 5,060 | Pfizer | Antikonvulsiva |
| 15 | Glatirameracetat | 4,650 | Teva Pharmaceutical Industries | Immunmodulatoren |
| 16 | Ranibizumab | 4,490 | Roche, Novartis | Monoklonale Antikörper: VEGF |
| 17 | Sitagliptin | 4,403 | MSD | Inhibitoren der Dipeptidylpeptidase 4 |
| 18 | Pegfilgrastim | 4,391 | Amgen | Granulozyten-Kolonie stimulierende Faktoren |
| 19 | Imatinib | 4,123 | Novartis | Proteinkinaseinhibitor |
| 20 | Tenofovir | 3,920 | Gilead Sciences | Nukleosidische Reverse-Transkriptase-Inhibitoren |
| 21 | Budesonid | 3,878 | AstraZeneca | Glucocorticoide |
| 22 | Insulin aspart | 3,878 | Novo Nordisk | Insulinanaloga |
| 23 | Tenofovir + Emtricitabin | 3,638 | Gilead Sciences | Nukleosidische Reverse-Transkriptase-Inhibitoren |
| 24 | Valsartan | 3,391 | Novartis | AT$_1$-Antagonisten |
| 25 | Celecoxib | 3,177 | Pfizer | COX-2-Hemmer |
| 26 | Oxycodon | 3,076 | Purdue Pharma | Opioid-Analgetika |
| 27 | Interferon Beta-1A | 3,024 | Biogen Idec | Interferone |
| 28 | Ezetimib | 3,022 | MSD | Cholesterin-Resorptionshemmer |
| 29 | Quetiapin | 2,588 | AstraZeneca | Atypische Neuroleptika |
| 30 | Insulin lispro | 2,584 | Eli Lilly and Company | Insulinanaloga |
| 31 | Enoxaparin-Natrium | 2,569 | Sanofi-Aventis | Antikoagulantien (Heparine) |
| 32 | Atorvastatin | 2,450 | Pfizer | Statine |
| 33 | Pemetrexed | 2,412 | Eli Lilly and Company | Zytostatika |
| 34 | Tadalafil | 2,393 | Eli Lilly and Company | PDE-5-Hemmer |